Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study

por Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Möllmann, Julia, Wied, Stephanie, Hohl, Mathias, Marx, Nikolaus, Lehrke, Michael
Publicado 2022

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized c...

por Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Schuh, Alexander, Altiok, Ertunc, Möllmann, Julia, Keszei, András P., Böhm, Michael, Marx, Nikolaus, Lehrke, Michael
Publicado 2021

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

por Thiele, Kirsten, Rau, Matthias, Hartmann, Niels‐Ulrik Korbinian, Möller, Marcus, Möllmann, Julia, Jankowski, Joachim, Keszei, András P., Böhm, Michael, Floege, Jürgen, Marx, Nikolaus, Lehrke, Michael
Publicado 2022

Long COVID‐19: Objectifying most self‐reported neurological symptoms

por Bungenberg, Julia, Humkamp, Karen, Hohenfeld, Christian, Rust, Marcus Immanuel, Ermis, Ummehan, Dreher, Michael, Hartmann, Niels‐Ulrik Korbinian, Marx, Gernot, Binkofski, Ferdinand, Finke, Carsten, Schulz, Jörg B., Costa, Ana Sofia, Reetz, Kathrin
Publicado 2022